This Phase 1b/2, open-label, multicenter dose escalation and expansion combination study of ADG126 in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA ® ...
Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), retaining the price target ...
Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback